PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box , today announced that the Institute of Virology at the University of Veterinary Medicine Vienna, one of the partners in PharmaCyte Biotech's international Diabetes Consortium, has completed the first round of safety testing of the Melligen cells in mice. The study showed that Melligen cells are as safe as the cells that were encapsulated with the Cell-in-a-Box technology and then used together with the cancer drug ifosfamide to treat patients with advanced pancreatic cancer in previously conducted clinical trials.